Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
Acta Biochim Biophys Sin (Shanghai). 2014 Mar;46(3):240-53. doi: 10.1093/abbs/gmt142. Epub 2013 Dec 29.
Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.
尽管免疫调节药物（IMiDs），如沙利度胺、来那度胺和泊马度胺，被广泛用于治疗多发性骨髓瘤（MM），但 IMiDs 的作用机制在很大程度上仍是未知的。在这篇综述中，我们将总结 IMiDs 在 MM 癌症治疗中的应用的最新进展，以及它们对免疫调节活性、抗血管生成活性、骨髓瘤细胞与骨髓基质细胞之间细胞表面黏附分子的干预、抗炎活性、抗增殖、促凋亡作用、细胞周期停滞以及抑制细胞迁移和转移的影响。此外，还将讨论潜在的 IMiDs 靶蛋白、IMiDs 靶蛋白的功能作用以及 IMiDs 耐药的潜在分子机制。我们希望通过呈现我们的初步讨论，这篇综述文章将有助于这些领域的进一步研究。
